PC Pilot and Feasibility Program Grant
The Porphyrias Consortium (PC) will support Pilot and Feasibility (P&F) grants for projects in the area of porphyrias and heme biosynthesis aimed at generating preliminary data for inclusion in larger grant applications. Applicants are able to request up to a $30,000 maximum for the award. These funds are to include a maximum of 8% in indirect costs to the award institution. Funds may be used for basic, translational and/or clinical studies.
These one-year Pilot and Feasibility (P&F) subawards:
- Applicants may be from any registered, domestic, eligible organization.
- Preference is given to early-stage investigators, such as postdocs and junior faculty, or established investigators embarking on a new research track (i.e., investigators not currently working in nonmalignant hematology).
- Research proposed must be within the mission of NIDDK Hematology and the scope of the PC. (https://www.niddk.nih.gov/research-funding/research-programs#hematologic-diseases) and (https://www.rarediseasesnetwork.org/cms/porphyrias)
- Applications require Institutional sign off by the applicant’s grant and contract office.
- Applications will be reviewed by a committee of peers.
REVIEW CRITERIA: Applications will be assessed for the likelihood that the results generated will lead to a future, larger grant applications and for the ability of the investigators to carry out the research in alignment with the PC.
Applications Due: April 15, 2020
Applications, only, should be uploaded as a single PDF file (11-point Arial font size and 0.5” margins) that must include:
1. Title, PI and any Key personnel or Sponsor, abstract, 1 page
2. Project description, significance, 1 page
3. Figures and references page, 1 page
4. Budget, and justification, 1 page
5. NIH-style biosketch.
Please send a single PDF of your application to: Program Director john.phillips@hsc.utah.edu, Program Managers Karli.hedstrom@mssm.edu & Hetanshi.naik@mssm.edu
2020 Call for Applications
Clinical Scholars is a three-year, team-based program for a wide variety of health professionals in community, clinical, or academic settings. By the end of the program, fellows will have gained the skills they need to appraise, synthesize, use the best evidence to guide practice and inform policy in addressing complex health problems in their teams, organizations, and communities.
RWJ is seeking up to 35 individuals (in teams of three to five) with the potential to become national change leaders in their focus areas and a demonstrated long-term commitment to fostering and achieving health equity.
Those selected for this program will engage in:
- Personal, in-depth leadership training in health equity and community engagement
- Collaborative work across disciplines and professions to tackle problems that emerge from complex systems in communities
- Robust and customizable distance-based learning (8–10 hours/month)
- Required in-person team meetings/activities three times per year
- Planning and implementation of your team’s “Wicked Problem Impact Project”
- Receipt of grant funds based on team size (from up to $315,000 for a three-person to $525,000 for a five-person team)
- Mentoring and networking across all Clinical Scholars cohorts, other RWJF leadership programs, and with experts nationwide.
Do you share the RWJ vision for leadership—and do you want to take the next step in your leadership journey? Explore the Clinical Scholars program.
Applications Due: March 11, 2020 (3 p.m. ET)
Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity
The Distinguished Innovator Awards provide outstanding scientists with substantial support (up to $250,000 per year for up to four years) to conduct novel research into the fundamental causes of systemic lupus erythematosus and so provide new directions towards a cure. The Lupus Research Alliance welcomes novel, hypothesis- or discovery-driven proposals using clinically relevant models in lupus research. The research proposal must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a cure, prevention, or highly effective therapy.
Applications will be judged primarily on the novelty and potential of the research proposal, and the strengths and track record of the investigator. Emphasis will be on the rationale for the hypothesis rather than the amount of preliminary data. Continuations of long-term research projects will not be considered. Successful applicants will be outstanding investigators who have demonstrated creativity and productivity in their field of research. We encourage applications from investigators in diverse disciplines including, but not limited to, immunology, genetics, molecular-, cell- and systems biology.
Letter of Intent Due: March 16, 2020